Hydrogen Sulfide and Substance P Levels in Patients with *Escherichia coli* and *Klebsiella pneumoniae* Bacteraemia

Sumeet Manandhar 1, Amy Scott-Thomas 1, Michael Harrington 2, Priyanka Sinha 1, Anna Pilbrow 3, Arthur Mark Richards 3, Vicky Cameron 3, Madhav Bhatia 1, * and Stephen T. Chambers 1

1 Department of Pathology and Biomedical Science, University of Otago, Christchurch 8140, New Zealand; sumeet.manandhar@postgrad.otago.ac.nz (S.M.); amy.scott-thomas@otago.ac.nz (A.S.-T.); 
priyanka.sinha@intergen.co.nz (P.S.); steve.chambers@otago.ac.nz (S.T.C.)
2 Microbiology Department, Canterbury Health Laboratories, Christchurch 8140, New Zealand; 
michael.harrington@cdhb.health.nz
3 Department of Medicine, University of Otago, Christchurch 8140, New Zealand; 
anna.pilbrow@otago.ac.nz (A.P.); mark.richards@cdhb.health.nz (A.M.R.); vicky.cameron@otago.ac.nz (V.C.)

* Correspondence: madhav.bhatia@otago.ac.nz; Tel.: +64-3-378-6238

Abstract: Hydrogen sulfide (H$_2$S) and substance P (SP) are known from animal models and in vitro studies as proinflammatory mediators. In this study, peripheral blood concentrations of H$_2$S and SP were measured in patients with *Escherichia coli* or *Klebsiella pneumoniae* bacteraemia. Fifty patients were recruited from general wards at Christchurch Hospital, during 2020–2021. Samples from age- and sex-matched healthy subjects previously recruited as controls for studies of cardiovascular disease were used as controls. The concentrations of H$_2$S were higher than controls on day 0, day 1, and day 2, and SP was higher than controls on all 4 days. The concentrations of H$_2$S were highest on day 0, whereas SP concentrations were higher on day 2 than other days. Interleukin-6 and C-reactive protein were significantly higher on day 0 and day 1, respectively. The concentrations of H$_2$S and SP did not differ between 15 non-septic (SIRS 0-1) and the 35 septic subjects (SIRS ≥ 2). Substance P concentrations were higher in subjects with abdominal infection than urinary tract infections on day 0 ($p = 0.0002$) and day 1 ($p = 0.0091$). In conclusion, the peak H$_2$S concentrations precede the SP peak in patients with Gram-negative bacteraemia, but this response varies with the site of infection.

Keywords: hydrogen sulfide; substance P; sepsis; *Escherichia coli*; *Klebsiella pneumoniae*

1. Introduction

*Escherichia coli* and *Klebsiella* species are closely related Gram-negative bacilli responsible for human infections and one of the most common causes of infection in hospitalized patients in New Zealand [1] and internationally [2]. These organisms are responsible for intra-abdominal and urinary tract infections and may precipitate sepsis or severe sepsis and have significant morbidity and mortality [3,4]. An increasing proportion of clinical isolates of *E. coli* and *Klebsiella* species are reported to be multi-resistant, including to beta lactam antibiotics, through the acquisition of extended-spectrum beta lactamase and carbapenemase enzymes [5,6]. Consequently, WHO has classified the development of new therapeutic approaches as critical and a priority [7,8]. This adds urgency to the investigation of new approaches that can mitigate the problem of antibiotic resistance and reverse Gram-negative-induced sepsis.

Hydrogen sulfide (H$_2$S) and substance P (SP) are well-known inflammatory mediators. H$_2$S and SP have been shown to have a proinflammatory role in animal models of experimental sepsis [9–14], and there is mounting evidence that H$_2$S plays a role in human infections. H$_2$S concentrations have been reported to be higher in patients with sepsis and septic shock in ICU than patients with similar physiological disturbance from non-infective insults [15], and in exhaled breath from septic neonates and children compared to
controls [16]. Patients with sepsis from *Pseudomonas aeruginosa* lung infections also have elevated H$_2$S concentrations in peripheral blood and, in addition, those surviving sepsis from *Pseudomonas* lung infections had higher concentrations of H$_2$S than non-survivors. A protective role for elevated H$_2$S concentrations was supported by reports of improved survival in a mouse model of *P. aeruginosa*-induced sepsis [17].

Studies of SP in humans with sepsis lack consistency. In ICU patients with sepsis, serum SP concentrations have been reported to be increased during the first week of sepsis [15] and higher concentrations have been reported in survivors than non-survivors [18]. In addition, lower SP levels in the plasma of both septic and septic shock patients compared with control subjects for all time points analysed (onset, 12 h, and 24 h) have been reported [19]. In post-operative patients, those with sepsis had higher SP concentrations than non-septic patients, although higher SP levels were associated with increased mortality in the late stages of sepsis [20].

In a recent study, we highlighted the translational potential of both H$_2$S and SP in patients with sepsis via a clinical study where higher circulating levels of H$_2$S (12 and 24 h after admission) and SP (48 h after admission) were associated with the inflammatory response but not in patients with related organ failure unrelated to sepsis [15]. These results suggest that alterations in circulating H$_2$S and SP concentrations may play an important role in the pathogenesis of sepsis and raises the possibility that the earlier peak in H$_2$S concentrations may influence subsequent SP expression. This study also suggested that H$_2$S and/or SP could be a potential therapeutic target for clinical sepsis. However, the ICU study included only very unwell patients suffering from diverse infections with a variable clinical course prior to admission to the ICU. In this study, the primary objective was to determine the concentrations of H$_2$S and SP in a cohort of patients admitted acutely to hospital with Gram-negative bacteraemia from either *E. coli* or *Klebsiella pneumoniae* and investigate the relationship between these concentrations to the clinical severity of sepsis at admission. The causes of bacteraemia are complex. Most originate from either ascending infection within the urinary tract causing pyelonephritis, or abdominal pathology such as biliary large bowel disease.

2. Results

2.1. Demographic Characters of Subjects at Presentation

In total, 50 subjects who met the inclusion criteria (see the Methods section) were recruited from 215 patients notified with *E. coli* or *Klebsiella* bacteraemia were approached (23%) for this study (Table 1). Thirty-four subjects had urinary tract infection, including one with ureteric stones. Sixteen subjects had an abdominal source of infection, including cholangitis (10), abdominal perforation (1), abdominal pain cause not identified (2), post biopsy (1), and two patients with neutropenic infection. The demographics and clinical characteristics of those recruited are presented in Table 1.

| Patient Characteristics                  | Patients | Controls |
|-----------------------------------------|----------|----------|
| Age—years                               | 72.5 (29–90) | 71.8 (37–86) |
| Female                                  | 33 (66%) | 32 (64%) |
| European                                | 44 (88%) | 46 (92%) |
| Māori                                   | 2 (4%)  | 2 (4%)  |
| Asian                                   | 2 (4%)  | 2 (4%)  |
| Other                                   | 2 (4%)  | 0 (0%)  |
| Charlson age                            | 3 (0–10) | -        |
| Urinary tract infection                 | 34 (68%) | 0 (0%)  |
| Abdominal infection                     | 16 (32%) | 0 (0%)  |
Table 1. Cont.

| Patient Characteristics | Patients | Controls |
|-------------------------|----------|----------|
| Neutrophils × 10⁹/L     | 13.85 (0–28.6) | - |
| CRP mg/L                | 118.5 (5–409)  | - |
| Creatinine mg/L         | 98 (56–734)   | 97 (75–136) |
| eGFR mL/s               | 52.5 (6–99)   | 65 (46.5–93) |
| EWS °                   | 4 (0–14)      | - |
| SIRS °°                 | 2 (0–4)       | - |
| **Co morbidities**      |           |          |
| Neutropenia ***         | 2 (4%)       | - |
| Cardiovascular disease  | 13 (26%)     | 0 (0%)   |
| Cerebrovascular disease | 6 (12%)      | 0 (0%)   |
| Congestive heart failure| 3 (6%)       | 0 (0%)   |
| Chronic obstructive     |             |          |
| pulmonary disease       | 6 (12%)      | - |
| Connective tissue disease| 6 (12%)     | - |
| Peptic ulcer disease    | 6 (12%)      | - |
| Solid tumour            | 12 (24%)     | 0 (0%)   |
| Liver disease           | 2 (4%)       | - |
| End-stage renal failure |             |          |
| /kidney transplant      | 4 (8%)       | - |
| Lymphoma                | 2 (4%)       | 0 (0%)   |
| Acute myeloid leukaemia | 1 (2%)       | 0 (0%)   |

*Early warning score; °Systemic inflammatory response syndrome; * Unless otherwise stated; ** Patients may have multiple co-morbidities; *** AML 1, Mantel cell lymphoma 1.

On admission, 15 subjects had a systemic inflammatory response syndrome (SIRS) score of 0 or 1, 35 had sepsis with a score of ≥2, and 24 had an early warning score (EWS) of 0–3 and 26 had a score of ≥4.

Subjects were discharged from hospital by the clinical teams as they recovered. The median hospital stay was 4 days (IQR 3–6.3, range 2–26). Four patients (8%) were admitted to intensive care. One subject (2%) died within 30 days of admission.

2.2. Plasma H₂S, SP, IL-6, and CRP Concentrations and Time Course

Plasma H₂S and SP concentrations in bacteraemic subjects are shown in Figure 1a,b. The median concentrations of H₂S in subjects were higher than controls (n = 50) on days 0, 1, and 2 (p < 0.0001, p < 0.0001, p = 0.0075, respectively) but not on day 3 (p = 0.09). Day 0 concentrations of H₂S (n = 44) were higher than days 1 (n = 40, p = 0.0011), 2 (n = 27, p < 0.0001), and 3 (n = 10, p = 0.003). Concentrations on day 1 were not significantly higher than on days 2 and 3 (p = 0.051 and 0.09), respectively.

The median concentrations of SP in subjects were higher than controls (n = 50) on days 0, 1, 2, and 3 (p < 0.007, p < 0.0001, p = 0.0001, p < 0.001 respectively).

The median concentrations of SP on day 0 (n = 44, IQR 0.0–0.42) did not differ from day 1 (n = 41, p = 0.55) but were higher on days 2 (n = 25, p < 0.0001) and 3 (n = 9, p = 0.0002). Interleukin-6 concentrations were highest on day 0 (n = 38) compared to days 1 (n = 40, p = 0.0401) and 2 (n = 29, p = 0.0036). C-reactive protein (CRP) was higher on days 1 (n = 40, p = 0.007) and 2 (n = 40, p = 0.0149) compared to day 0 (n = 46) (Figure 2a,b).

The day 0 H₂S concentration correlated with the concentration of SP on day 2 (p = 0.022) while the other correlations did not reach significance.

There was insufficient data (<8 samples) on days 4 and 5 for analysis, as most patients were recovered and discharged after day 3.
There was insufficient data (<8 samples) on days 4 and 5 for analysis, as most patients were recovered and discharged after day 3.

Plasma levels of IL-6 and CRP in E. coli- and K. pneumoniae-infected patients. Plasma samples were collected from patients at different time intervals (days 0, 1, 2, day 3). Controls were healthy age- and sex-matched subjects. Plasma H$_2$S (a) and SP (b) concentrations on days 0, 1, 2, and 3 from patients were compared with each other and non-septic control subjects. Results are expressed as the median with the interquartile range (box plot) with the maximum and minimum value (whiskers plot). Two-tailed paired Mann–Whitney tests were performed. # p < 0.0001 vs. control; + p < 0.01 vs. control; † p < 0.05 vs. control; **** p < 0.0001 vs. day 0; *** p < 0.001 vs. day 0; ** p < 0.01 vs. day 0; * p < 0.05 vs. day 0.

Figure 1. Plasma levels of H$_2$S and SP in E. coli- and K. pneumoniae-infected patients. Plasma samples were collected from patients at different time intervals (days 0, 1, 2, day 3). Controls were healthy age- and sex-matched subjects. Plasma H$_2$S (a) and SP (b) concentrations on days 0, 1, 2, and 3 from patients were compared with each other and non-septic control subjects. Results are expressed as the median with the interquartile range (box plot) with the maximum and minimum value (whiskers plot). Two-tailed paired Mann–Whitney tests were performed. # p < 0.0001 vs. control; + p < 0.01 vs. control; † p < 0.05 vs. control; **** p < 0.0001 vs. day 0; *** p < 0.001 vs. day 0; ** p < 0.01 vs. day 0; * p < 0.05 vs. day 0.

Figure 2. Plasma levels of IL-6 and CRP in E. coli- and K. pneumoniae-infected patients. Plasma samples were collected on days 0, 1, 2, and 3. Plasma IL-6 (a) and CRP (b) levels on days 1, 2, and 3 in patients are compared with the day 0 results. Results are expressed as the median with the interquartile range (box plot) with the maximum and minimum value (whiskers plot). Two-tailed paired Mann–Whitney tests were performed. ** p < 0.01 vs. day 0; * p < 0.05 vs. day 0.
2.3. Comparison of Plasma H$_2$S, SP, IL-6, and CRP Concentrations in Urinary and Abdominal Infection

Because of the lack of a relationship between the severity scores and the levels of H$_2$S and SP, the data was analysed by site of infection. There was no significant difference in the age, gender, systemic inflammatory response syndrome (SIRS), early warning score (EWS), CRP, or H$_2$S concentrations between the urinary and abdominal infection groups (Table 2). However, SP concentrations were significantly lower in the urinary infection groups compared to abdominal infection on days 0 ($p = 0.0002$) and 1 ($p = 0.0091$).

Table 2. Comparison of plasma H$_2$S, SP, IL-6, and CRP concentrations between urinary tract and abdominal infections. The SIRS and EWS scores and white blood cell count were obtained from observations and samples taken during the first 12 h after admission. Data are expressed as the median with the interquartile range unless otherwise stated.

| Day   | Abdomen | Urinary Tract | $p$ Value |
|-------|---------|---------------|-----------|
|       | Number  | Age           | Gender    | SIRS   | EWS       | White blood cell count $\times 10^9$/L | $p$ Value |
|       |         | 16            | 34        |        | 0.99      |                                      |           |
|       |         | 73 (62–82)    | 74 (63–82) | 0.8919 | 0.7664    |                                      |           |
|       | Gender  | 6 (37.5%)     | 11 (32.4%)| 2 (1–3) | 2 (1–4)   |                                      |           |
|       | EWS     | 3.5 (1.3–5.8) | 4 (2–5.3) | 0.0492 |           |                                      |           |
| H$_2$S| Day 0   | 6.1 (5.2–8.1) | 4.9 (3.3–7.1) | 0.0567 |           |                                      |           |
|       | Day 1   | 4.2 (3.4–4.6) | 3.3 (2.5–5.3) | 0.2764 |           |                                      |           |
|       | Day 2   | 3.5 (2.7–4.4) | 2.9 (2.2–3.8) | 0.2120 |           |                                      |           |
|       | Day 3   | 3.3 (2.5–4.2) | 2.5 (2–4.1)  | 0.4206 |           |                                      |           |
| SP    | Day 0   | 0.47 (0.09–2) | 0 (0–0.92)  | 0.0002 |           |                                      |           |
|       | Day 1   | 0.7 (0.16–3.3)| 0.026 (0–0.63) | 0.0091 |           |                                      |           |
|       | Day 2   | 0.7 (0.42–4.1)| 0.13 (0.003–4.8) | 0.2095 |           |                                      |           |
|       | Day 3   | 2.2 (0.22–11)| 1.1 (0.46–3.2) | 0.9048 |           |                                      |           |
| IL-6  | Day 0   | 49.18 (5.70–290.1)| 59.23 (22.53–114.1) | 0.8911 |           |                                      |           |
|       | Day 1   | 14.35 (6.36–193.2)| 31.99 (11.71–53.66) | 0.3395 |           |                                      |           |
|       | Day 2   | 26.77 (9.18–170.6)| 11.41 (4.18–27.21) | 0.1816 |           |                                      |           |
|       | Day 3   | 2.86 (1.24–4.48)| 16.76 (5.24–29.77) | 0.1905 |           |                                      |           |
| CRP   | Day 0   | 160 (22–160.5)  | 148 (71–219)  | 0.1426 |           |                                      |           |
|       | Day 1   | 147.5 (123.5–232)| 187.5 (151.5–274) | 0.0871 |           |                                      |           |
|       | Day 2   | 216.5 (183.5–287)| 273.5 (215–397)  | 0.2190 |           |                                      |           |
|       | Day 3   | 183.5 (100.5–216.5)| 215 (125.5–273.5) | 0.6700 |           |                                      |           |

In the urinary tract infection group, there was a significant correlation between the SIRS score and H$_2$S concentration on days 0 ($p = 0.034$) and 1 ($p = 0.037$), and between the EWS score and H$_2$S concentration on days 0 ($p = 0.056$) and 1 ($p < 0.0005$) (Supplementary Table S1b). There was a significant correlation between the SP concentration and SIRS ($p = 0.02$) and EWS ($p = 0.033$) on day 0 only.

3. Discussion

In this study of bacteraemia subjects with the Gram-negative organisms, *E. coli* and *K. pneumonia*, the organisms responsible for most cases of Gram-negative sepsis, we found that the clinical severity on admission (SIRS and EWS) was not related to the measured blood concentrations of either H$_2$S or SP.

H$_2$S concentrations were most elevated at the time of admission and decreased from day 1 to day 3 after medical intervention. The median SP concentrations followed a different time course and increased progressively over the observations period, although they were higher on days 0 and 1 compared with controls. These results are consistent with our previous ICU study, where H$_2$S and SP levels were elevated in sepsis, but are independent of the clinical parameters used to measure severity, such as APACHE II and III, SAPS II, and SOFA [15]. They also followed a similar time course to the changes observed in our ICU study [15,16]. The results add to previous knowledge by showing that H$_2$S concentrations
may be elevated in bacteraemic but not septic subjects and suggest that this response is triggered as part of an appropriate initial response to infection by the host.

The high SP concentrations on days 2 and 3 may in part reflect the severity of the infection in those remaining in hospital as those who had recovered, and presumably were less severely affected, had been discharged from hospital promptly and were unavailable for sampling. These results are consistent with other studies that have found SP concentrations were elevated during the late stages of lethal sepsis [15,20]. During the first week of admission, surviving septic patients had higher serum SP levels than non-survivors during the first week, suggesting the role of SP as a biomarker of sepsis mortality [18,21].

The comparison of the results between abdominal and urinary tract infections yielded a new perspective. Firstly, there was strong evidence that SP concentrations were higher on both day 0 and day 1 in those with abdominal infection than those with urinary tract infection, although both had similar SIRS and EWS scores. This suggests that the contribution of the SP pathway to the inflammatory response may be influenced by the site of infection, but factors such as the length of time the subjects were unwell before being admitted to hospital or the polymicrobial infections commonly found in abdominal but not urinary tract infections may confound this finding. Secondly, there was evidence that day 0 H2S concentrations were correlated with the SIRS and EWS in urinary tract infection but not in abdominal infections. Interestingly, both the EWS and SIRS scores were strongly negatively correlated with day 1 H2S concentrations in abdominal infections, suggesting that H2S concentrations may fall quickly in subjects with the most marked early clinical manifestation of infection. Finally, the results are consistent with the observation that elevated SP concentrations are more reflective of ongoing established infection rather than the first phase of an acute response. On day 0, SP concentrations correlated negatively with both the SIRS and EWS in both urinary and abdominal infections but not at other time points. Additionally, SP on day 1 also correlated with the subsequent length of hospital stay in abdominal infections.

The sequence of the early increase in the H2S concentration followed by a rise in SP in this and previous clinical studies raises the questions as to whether H2S may play a role in triggering the SP response. Previous studies have established H2S and SP as proinflammatory mediators in various mouse models [11,21–26]. Following cecal ligation and puncture (CLP)-induced sepsis, there was an increase in tissue H2S-synthesising activity, plasma H2S levels, and tissue and plasma SP levels. H2S donor, Na2S and NaHS, administration has been demonstrated to elevate local and systemic inflammation, whereas DL-propargylglycine (an inhibitor of cystathionine-γ-lyase H2S-synthesizing enzyme) and neurokinin-1 receptor (substance P receptor) antagonist treatment protected against the sepsis-induced systemic inflammatory response and multiple organ dysfunction in mice [11,12,24]. Furthermore, gene knockout of cystathionine-γ-lyase and preprotackykinin (PPTA gene that codes for SP) in mice protected against CLP sepsis that induced local and systemic inflammation [9,10,13,26]. H2S upregulated SP synthesis and its circulating blood concentration in a mouse model [23,24,27]. However, genetic deletion of PPTA has no effect on the H2S level following CLP-induced sepsis, demonstrating that SP is located downstream of H2S in the inflammatory pathway. In addition, SP levels in CLP-induced sepsis were not restored to the level of sham-operated mice, even after the inhibition of H2S formation, suggesting that the pathogenesis of sepsis is a complicated system, where the synthesis of SP is influenced by other mediators in addition to H2S [28]. In addition, H2S and SP have shown direct effects on the expression level of chemokines and cytokines independently of each other in vitro [29–32]. These studies show that although H2S acts via SP in inflammation, these two inflammatory mediators have pathways that may be independent of each other. Our recent clinical study showed that the H2S concentration was elevated at both the 12- and 24-h time points while SP levels were elevated from 48 to 96 h [15]. Similarly, in this study, we showed that H2S levels increase early (day 0) in the inflammatory response while the SP level increases later (day 2 and day 3), supporting the evidence that H2S may be responsible for upregulating SP during sepsis. However, the
discrepancy in the SP level, with H$_2$S showing alteration of its level relative to the site of infection, raises the question of whether SP is influenced by various pathways other than the H$_2$S pathway as shown by our previous mouse model experiments.

C-reactive protein levels have been of great clinical interest for early diagnosis of infection and monitoring its treatment response as they are easily measured and related to the severity of the systemic inflammatory response [33–37]. The results of the present study show a higher plasma concentration of CRP, peaking on day 1, but there was no significant correlation between the H$_2$S and SP concentrations in either the urinary tract infection or abdominal infection group, although this may become apparent in a larger cohort. IL-6 serves as a major mediator during the early phase of the acute response to inflammation in sepsis, and its clinical importance has been assessed in several studies on patients with various septic conditions [38–41]. The early rise in the IL-6 concentrations was similar to the plasma H$_2$S levels. Overall, these results suggest IL-6 and H$_2$S may serve as early markers of inflammation during $E$. coli- and $K$. pneumoniae-induced sepsis.

Limitations: Although this study conclusively shows that H$_2$S and SP have an important role in patients with Gram-negative bacteraemia, the sample size is an obvious limitation of this study. Further investigation with a larger patient population with well-defined clinical and microbiological infections is required to understand the significance of H$_2$S and SP in human sepsis. The methylene blue method (assay), which is used to quantify H$_2$S levels, also quantifies other H$_2$S-related compounds. This assay was used as it is convenient for quantifying many clinical samples and has been used in animal studies with success. The use of methods with higher specificity for H$_2$S would be advantageous.

In conclusion, this translational study demonstrated that higher concentrations of H$_2$S correlated with the very early and SP with the later phase of the inflammatory response in $E$. coli and $K$. pneumoniae bacteraemia and suggests there may be variation in the pathway of activation of the inflammatory response between urinary tract and abdominal infection. This has important implications for future clinical research of H$_2$S and SP in the ICU, where infection at multiple sites, including the lung, skin and soft tissue, and bone and joint infection, may be included with abdominal and urinary tract infection. Caution should also be used when interpreting the results of animal studies of single-site infections to avoid overgeneralising the systemic implications of this study. Further studies are needed to determine the potential role of the H$_2$S and SP pathways to assess patient severity and novel therapeutic approaches for these patients.

4. Materials and Methods

4.1. Study Design and Selection of Subjects

This study was an observational prospective prognostic cohort study of patients admitted to Christchurch Hospital, Christchurch, New Zealand with $E$. coli or $K$. pneumoniae bacteraemia. Christchurch Hospital provides secondary and tertiary care for the Canterbury area of New Zealand, serving a population of about 550,000 people. The protocol, participant informed consent form, participant information sheet, family/whānau consent form, and questionnaires were approved by a Human Health and Disability Ethics Committee (Ethics ref: 20/STH/5). Written informed consent was provided by all patients who participated in this study. Patients who were confused, admitted during the weekend, or discharged within 24 h were not able to be approached to take part in this study.

Procedures

Patients admitted to hospital with clinical suspicion of sepsis such as signs and symptoms of acute infection and an elevated body temperature had blood cultures drawn as part of their clinical work up. Temperature, respiratory rate, heart rate, blood temperature, and oxygen saturation were recorded every 6–8 h onto an electronic database by clinical staff.

Blood cultures and clinical specimens for routine haematological, biochemical, and microbiological studies were processed at the clinical laboratory (Canterbury Health Labo-
ratories). Blood was cultured using an automated culture system (Bactec SX). Antimicrobial susceptibility was measured with a BD Phoenix™ instrument to determine the minimum inhibitory concentrations. Antimicrobial therapy was administered by the clinical team responsible for the patient according to the hospital guidelines. Investigators were notified of positive blood cultures with a Gram-negative organism online as soon as they became positive and were approached for suitability consent for enrolment.

The inclusion criteria were:
- Any patient with *E. coli* or *K. pneumoniae* isolated from the blood or sterile site (e.g., joints) with or without sepsis’
- Aged ≥ 18 years;
- Able to provide informed consent;
- Investigators notified within 24 h of admission.

The exclusion criteria were:
- All patients with sepsis caused by other organisms. If it was a polymicrobial infection, cases were included as long one organism was identified as *E. coli* or *K. pneumoniae*;
- COVID-related restrictions that denied access to the hospital for research studies;
- Patient unable to provide informed consent.

4.2. Definitions

Bacteraemia was defined as isolation of *E. coli* or *K. pneumonia* from one or more sets of blood culture. Two sets of blood cultures were taken routinely on admission, although further blood cultures were taken at the discretion of the clinical team responsible for their care.

Sepsis was defined as a systemic inflammatory response syndrome (SIRS) score of >2 [42] or an early warning score (EWS) of >4 based on [43,44], with the highest recorded in the first 24 h of admission to hospital [45,46]. The qSOFA score could not be measured as patients with confusion were excluded.

4.3. Blood Collection and Plasma Preparation

4.3.1. Day 0 Samples

Blood samples for biochemical and haematological analyses collected on admission for patient evaluation were separated and stored in a refrigerated auto-analysing suite. Residual ethylene-diamine-tetra-acetic acid (EDTA) blood samples of newly enrolled subjects were retrieved daily. A pilot study showed H$_2$S and SP are stable in this system and suitable for retrieval and analysis within 24 h.

4.3.2. Follow-Up Samples

Blood was taken daily while the subjects were in hospital for up to 5 days. Blood samples were drawn through venepuncture and collected into 6-mL EDTA vacutainer tubes and placed on ice for transport to the laboratory, and centrifuged at 1000 × g for 10 min at 4 °C. Clear plasma was collected and aliquoted into multiple tubes. Assays for C-reactive protein (CRP) were performed as per the established protocols at Canterbury Health Laboratory, Christchurch, New Zealand. Remaining plasma was stored as aliquots at –80 degrees C. An individual aliquot was used for each analysis, which was carried out in batches.

4.3.3. Control Samples

These were selected from an archive of 3358 biobanked samples from patients recruited as controls for studies of cardiovascular disease (CVD), who also consented for their samples to be used in other studies (Trial Registry ACTRN1260500448640) [47]. This study was approved by the Upper South A Ethics Committee (Reference No. CTY/01/05/062), and each participant provided written informed consent. The inclusion criteria were that they were clinically well and had no history or hospital admissions for CVD, no self-reported history of diabetes (type 1 or type 2), hypertension, high cholesterol, joint
disease, gut disease, skin disease, thyroid disease, asthma, or cancer. One to one matching was performed using the MatchIt package (https://github.com/kosukeimai/MatchIt, accessed on 28 February 2022) [48] in R [49], which identified 50 subjects matching for age (median 72.5 for bacteraemia patients and 71.8 for controls ($p = 0.927$)), gender ($p = 0.834$), and ethnicity.

4.4. Measurement of Plasma H$_2$S Concentration

Hydrogen sulfide was measured using a spectrophotometric assay (methylene blue method) as described by Gaddam et al. [15]. In brief, plasma samples were mixed with equal volumes of phosphate buffer and a mixture of pyridoxal phosphate L-cysteine, zinc acetate, N,N-dimethyl-p-phenylenediamine sulphate, and FeCl$_3$•HCl. The mixture was incubated in the dark for 20 min at room temperature after which trichloroacetic acid was added to denature the protein and stop the reaction. Samples were centrifuged at $7700 \times g$ for 5 min at 4°C and 150 $\mu$L supernatant transferred into a 96-well microplate. Absorbance was measured at 670 nm (Multiskan Go, Thermofisher). H$_2$S was calculated using a calibration curve of sodium sulfide (0.4–25 $\mu$M) and H$_2$S levels were expressed as $\mu$M.

4.5. Measurement of Plasma Substance P Concentration

Human plasma SP concentrations were measured using ELISA (Bachem; Peninsula Laboratories, Bubendorf, Switzerland) according to the manufacturer’s protocol. Absorbance was measured at 450 nm by a spectrophotometer (Multiskan Go, Thermofisher, Vantaa, Finland). SP levels were expressed as ng per 100 $\mu$L plasma.

4.6. Measurement of Plasma Interleukin-6 Concentration

Plasma IL-6 levels were measured using sandwich ELISA Duoset kits (R&D systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. Assay absorbance was measured at 450 nm on a spectrophotometer (Multiskan Go, Thermofisher) with 540 nm correction. The IL-6 concentration was expressed as pg/mL in plasma.

4.7. Statistical Analysis

Continuous variables were summarized with descriptive analyses that included medians, ranges, and interquartile ranges where appropriate. Categorical variables are given as frequencies and percentages. Exploratory hypothesis testing was carried out using the Mann–Whitney U test. Statistical analyses were performed by GraphPad software (version 9, Prism, San Diego, CA, USA). Comparison between groups used the two-tailed Mann–Whitney U test and Spearman coefficient for correlations. A $p$-value of less than 0.05 was considered as statistically significant.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23158639/s1.

Author Contributions: Conceptualization, S.T.C. and M.B.; methodology, S.T.C. and M.B.; formal analysis, S.M. and S.T.C.; investigation, S.T.C., A.S.-T., M.H., P.S., A.P., A.M.R., V.C., and S.M.; resources, S.T.C., A.S.-T. and M.B.; data curation, S.T.C., A.S.-T., A.P., A.M.R., V.C. and M.H.; writing—original draft preparation, S.M., S.T.C., A.S.-T. and M.B.; writing—review and editing, S.M., S.T.C., A.S.-T., M.H., P.S., A.P., A.M.R., V.C. and M.B.; visualization, S.T.C., A.S.-T., M.H. and P.S.; project administration, S.T.C. and A.S.-T.; funding acquisition, S.T.C. and M.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by a University of Otago Research Grant. Funders of the Canterbury Healthy Volunteers Cohort (Health Research Council Programme Grant # 11/170, Heart Foundation of New Zealand Small Project Grant # 1838 and the Christchurch Heart Institute Trust).
Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Health and Disability Ethics Committee (20/STH/5, approved 14 April 2020). The Canterbury Healthy Volunteers study was approved by the Upper South A Ethics Committee (Reference No. CTY/01/05/062), and each participant provided written, informed consent.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Informed consent was obtained from the patient(s) to publish data from the study.

Data Availability Statement: The data presented in this study are available on request from Professor Stephen T Chambers. The data are not publicly available and stored on a secure system at the University of Otago, Christchurch.

Acknowledgments: Phlebotomy and microbiology teams at Canterbury Health Laboratories.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Williamson, D.A.; Lim, A.; Wiles, S.; Roberts, S.A.; Freeman, J.T. Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005–2011. BMC Infect. Dis. 2013, 13, 385. [CrossRef] [PubMed]
2. Stoll, B.J.; Hansen, N.I.; Sánchez, P.J.; Faix, R.G.; Poindexter, B.B.; Van Meurs, K.P.; Bizzarro, M.J.; Goldberg, R.N.; Frantz, I.D.; Hale, E.C.; et al. Early onset neonatal sepsis: The burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011, 127, 817–826. [CrossRef] [PubMed]
3. Peleg, A.Y.; Hooper, D.C. Hospital-Acquired Infections Due to Gram-Negative Bacteria. N. Engl. J. Med. 2010, 362, 1804–1813. [CrossRef] [PubMed]
4. Daga, A.P.; Koga, V.L.; Soncini, J.G.M.; De Matos, C.M.; Perugini, M.R.E.; Pelisson, M.; Kobayashi, R.; Vespro, E.C. Escherichia coli Bloodstream Infections in Patients at a University Hospital: Virulence Factors and Clinical Characteristics. Front. Cell. Infect. Microbiol. 2019, 9, 191. [CrossRef] [PubMed]
5. Ruppé, É.; Woerther, P.-L.; Barbier, F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann. Intensiv. Care 2015, 5, 61. [CrossRef] [PubMed]
6. Shaikh, S.; Fatima, J.; Shakil, S.; Rizvi, S.M.D.; Kamal, M.A. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Studi J. Biol. Sci. 2015, 22, 90–101. [CrossRef] [PubMed]
7. Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [CrossRef]
8. WHO. Antimicrobial Resistance—Global Report on Surveillance; WHO: Lyon, France, 2014; pp. 1–232.
9. Gaddam, R.R.; Fraser, R.; Badie, A.; Chambers, S.; Cogger, V.C.; Le Couteur, D.G.; Ishii, I.; Bhatia, M. Cystathionine-Gamma-Lyase Gene Deletion Protects Mice against Inflammation and Liver Sive Injury following Polymicrobial Sepsis. PLoS ONE 2016, 11, e0160521. [CrossRef] [PubMed]
10. Gaddam, R.R.; Chambers, S.; Fraser, R.; Cogger, V.C.; Le Couteur, D.G.; Ishii, I.; Bhatia, M. Cystathionine-Gamma-Lyase-Derived Hydrogen Sulfide-Regulated Substance P Modulates Liver Sive Fenestrations in Caecal Ligation and Puncture-Induced Sepsis. Int. J. Mol. Sci. 2019, 20, 3191. [CrossRef]
11. Hegde, A.; Zhang, H.; Mookhala, S.M.; Bhatia, M. Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. J. Leukoc. Biol. 2007, 82, 678–685. [CrossRef] [PubMed]
12. Zhang, H.; Mookhala, S.M.; Bhatia, M. Endogenous Hydrogen Sulfide Regulates Inflammatory Response by Activating the ERK Pathway in Polymicrobial Sepsis. J. Immunol. 2008, 181, 4320–4331. [CrossRef]
13. Puneet, P.; Hegde, A.; Ng, S.W.; Lau, H.Y.; Lu, J.; Mookhala, S.M.; Bhatia, M. Preprotachykinin-A Gene Products Are Key Mediators of Lung Injury in Polymicrobial Sepsis. J. Immunol. 2006, 176, 3813–3820. [CrossRef] [PubMed]
14. Manandhar, S.; Sinha, P.; Ejiviale, G.; Bhatia, M. Hydrogen Sulfide and its Interaction with Other Players in Inflammation. Adv. Exp. Med. Biol. 2021, 1315, 129–159. [CrossRef]
15. Gaddam, R.R.; Chambers, S.; Murdoch, D.; Shaw, G.; Bhatia, M. Circulating levels of hydrogen sulfide and substance P in patients with sepsis. J. Infect. 2017, 75, 293–300. [CrossRef] [PubMed]
16. Bee, N.; White, R.; Petros, A.J. Hydrogen Sulfide in Exhaled Gases from Ventilated Septic Neonates and Children: A Preliminary Report. Pediatr. Crit. Care Med. 2017, 18, e327–e332. [CrossRef]
17. Reniers, G.; Droggit, D.-E.; Katrini, K.; Koufargyris, P.; Gkavogianni, T.; Karakike, E.; Antonakos, N.; Damoraki, G.; Karageorgos, A.; Sabraco, L.; et al. Host cystathionine-γ lyase derived hydrogen sulfide protects against Pseudomonas aeruginosa sepsis. PLoS Pathog. 2021, 17, e1009473. [CrossRef] [PubMed]
18. Lorente, L.; Martín, M.M.; Pérez-Cejas, A.; Ferreres, J.; Solé-Violán, J.; Labarta, L.; Díaz, C.; Jiménez, A. Sustained Low Serum Substance P Levels in Non-Surviving Septic Patients. Int. J. Mol. Sci. 2017, 18, 1531. [CrossRef]
19. Arnalich, F.; Sánchez, J.F.; Martínez, M.; Jiménez, M.; López, J.; Vázquez, J.J.; Hernanz, A. Changes in plasma concentrations of vasoactive neuropeptides in patients with sepsis and septic shock. *Life Sci.* 1995, 56, 75–81. [CrossRef]

20. Beer, S.; Weighardt, H.; Emmanuilidis, K.; Harzenetter, M.D.; Matevosian, E.; Heidecke, C.-D.; Bartels, H.; Siewert, J.-R.; Holzmann, B. Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis. *Crit. Care Med.* 2002, 30, 1794–1798. [CrossRef]

21. Zhang, H.; Zhi, L.; Moohchhala, S.; Moore, P.K.; Bhatia, M. Hydrogen sulfide acts as an inflammatory mediator in cecal ligation and puncture-induced sepsis in mice by upregulating the production of cytokines and chemokines via NF-kappaB. *Am. J. Physiol. Lung Cell Mol. Physiol.* 2007, 292, L960–L971. [CrossRef]

22. Hegde, A.; Tamizhselvi, R.; Manikandan, J.; Melendez, A.J.; Moohchhala, M.B. Substance P in polymicrobial sepsis: Molecular fingerprint of lung injury in preprotachykinin-A/-/ mice. *Mol. Med.* 2010, 16, 188–198. [CrossRef] [PubMed]

23. Zhang, H.; Zhi, L.; Moore, P.K.; Bhatia, M. Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. *Am. J. Physiol. Cell. Physiol.* 2006, 290, L1193–L1201. [CrossRef] [PubMed]

24. Zhang, H.; Zhi, L.; Moohchhala, S.M.; Moore, P.K.; Bhatia, M. Endogenous hydrogen sulfide regulates leukocyte trafficking in cecal ligation and puncture-induced sepsis. *J. Leukoc. Biol.* 2007, 82, 894–905. [CrossRef] [PubMed]

25. Badiei, A.; Chambers, S.T.; Gaddam, R.R.; Bhatia, M. Cystathionine-γ-lyase gene silencing with siRNA in monocytes/macrophages attenuates inflammation in cecal ligation and puncture-induced sepsis in the mouse. *J. Biosci.* 2016, 41, 87–95. [CrossRef]

26. Ng, S.W.; Zhang, H.; Hegde, A.; Bhatia, M. Role of preprotachykinin-A gene products on multiple organ injury in LPS-induced endotoxemia. *J. Leukoc. Biol.* 2008, 83, 288–295. [CrossRef]

27. Bhatia, M.; Zhi, L.; Zhang, H.; Ng, S.-W.; Moore, P.K. Role of substance P in hydrogen sulfide-induced pulmonary inflammation in mice. *Am. J. Physiol. Cell. Physiol.* 2006, 291, L1896–L1904. [CrossRef]

28. Zhang, H.; Hegde, A.; Ng, S.W.; Adhikari, S.; Moohchhala, S.M.; Bhatia, M. Hydrogen Sulfide Up-Regulates Substance P in Polymicrobial Sepsis-Associated Lung Injury. *J. Immunol.* 2007, 179, 4153–4160. [CrossRef]

29. Sun, J.; Rammuth, R.D.; Tamizhselvi, R.; Bhatia, M. Role of protein kinase C and phosphoinositide 3-kinase-Akt in substance P-induced proinflammatory pathways in macrophage. *FASEB J.* 2009, 23, 997–1010. [CrossRef]

30. O’Connor, T.M.; O’Connell, J.; O’Brien, D.I.; Goode, T.; Bredin, C.P.; Shanahan, F. The role of substance P in inflammatory disease. *J. Cell. Physiol.* 2004, 201, 167–180. [CrossRef] [PubMed]

31. Whitman, M.; Li, L.; Rose, P.; Tan, C.-H.; Parkinson, D.B.; Moore, P.K. The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. *Antioxid. Redox Signal.* 2010, 12, 1147–1154. [CrossRef] [PubMed]

32. Badiel, A.; Rivers-Auty, J.; Ang, A.D.; Bhatia, M. Inhibition of hydrogen sulfide production by gene silencing attenuates inflammation in cecal ligation and puncture-induced sepsis in the mouse. *Int. J. Mol. Sci.* 2019, 20, 5843–5868. [CrossRef]

33. Zhang, H.; Zhi, L.; Moochhala, S.; Moore, P.K.; Bhatia, M. C-reactive Protein as a Diagnostic Test of Sepsis in the Critically Ill. *Crit. Care Med.* 2002, 30, 1794–1798. [CrossRef]

34. yarn, S.M.; Soni, N.; Sheldon, J.C. C-reactive protein as an indicator of resolution of sepsis in the intensive care unit. *Intensiv. Care Med.* 1995, 21, 602–605. [CrossRef] [PubMed]

35. Matson, A.; Soni, N.; Sheldon, J. C-reactive protein as a diagnostic test of sepsis in the critically ill. *Anaesth. Intensiv. Care* 1991, 19, 182–186. [CrossRef] [PubMed]

36. Meisner, M.; Tschaikowsky, K.; Palmaers, T.; Schmidt, J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. *Crit. Care 1999, 3, 45–50. [CrossRef]

37. Martín, H.; Olander, B.; Norman, M. Reactive hyperemia and interleukin 6, interleukin 8, and tumor necrosis factor-alpha in the diagnosis of early-onset neonatal sepsis. *Pediatrics 2001, 108, E61.* [CrossRef]

38. Leal, Y.A.; Alvarez-Nemegyei, J.; Lavadores-May, A.L.; Girón-Carrillo, J.L.; Cedillo-Rivera, R.; Velazquez, J.R. Cytokine profile as diagnostic and prognostic factor in neonatal sepsis. *J. Matern. Neonatal Med.* 2019, 32, 2830–2836. [CrossRef]

39. Hack, C.E.; De Groot, E.R.; Felt-Bersma, R.J.; Nuijens, J.H.; Van Schijndel, R.J.S.; Aarden, L.A.; Goede, T.; Bredin, C.P.; Shanahan, F. The role of substance P in inflammatory disease. *J. Leukoc. Biol.* 2002, 72, 1704–1710. [CrossRef]

40. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knaus, W.A.; Schein, R.M.H.; Sibbald, W.J. Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. *Chest 1992, 101, 1644–1655. [CrossRef] [PubMed]

41. Morgan, R.; Wright, M. An Early Warning Scoring System for detecting developing critical illness. *Clin. Intensive Care 1997, 8, 100.*

42. Subbe, C.P.; Kruger, M.; Rutherford, P.; Gemmel, L. Validation of a modified Early Warning Score in medical admissions. *QJM 2001, 94, 521–526. [CrossRef] [PubMed]

43. Usman, O.A.; Ward, M.A. Comparison of SIRS, qSOFA, and NEWS for the early identification of sepsis in the Emergency Department. *Am. J. Emerg. Med.* 2019, 37, 1490–1497. [CrossRef] [PubMed]
46. National Early Warning Score (NEWS) 2- Standardising the Assessment of Acute-Illness Severity in the NHS. Royal Collage of Physicians. 2017. Available online: https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2 (accessed on 28 February 2022).

47. Ellis, K.L.; Frampton, C.M.; Pilbrow, A.P.; Troughton, R.W.; Doughty, R.N.; Whalley, G.A.; Ellis, C.J.; Skelton, L.; Thomson, J.; Yandle, T.G.; et al. Genomic Risk Variants at 1p13.3, 1q41, and 3q22.3 Are Associated with Subsequent Cardiovascular Outcomes in Healthy Controls and in Established Coronary Artery Disease. Circ. Cardiovasc. Genet. 2011, 4, 636–646. [CrossRef] [PubMed]

48. Ho, D.E.; Imai, K.; King, G.; Stuart, E.A. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Political Anal. 2007, 15, 199–236. [CrossRef]

49. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2020; Available online: https://www.R-project.org/ (accessed on 28 February 2022).